BGB-283 - Lifirafenib

Based on 3 reference(s) in Google Scholar 8 10 3

Axon 3862

CAS [1446090-77-2]

MF C25H17F3N4O3
MW 478.42

  • Purity: 99%
  • Optical purity: 99%
  • Soluble in DMSO



BGB-283 is an orally available dual RAF kinase/EGFR inhibitor. It potently inhibits BRAF family proteins (wild-type ARAF, BRAF, CRAF and BRAF V600E), BRAF(V600E)-activated ERK phosphorylation and cell proliferation, and demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAF(V600E) and EGFR mutation/amplification. Further, it uniquely displays inhibitory activity towards both BRAF monomeric and dimeric forms, and is considered to be the next generation inhibitor to potentially address resistances associated with increased BRAF dimer formation in response to treatment with first-generation BRAF inhibitors.

KEYWORDS: BGB-283 | Supplier | RAF kinase and EGFR inhibitor | Lifirafenib | BGB283 | BGB 283 | CT-BGB283 | CAS [1446090-77-2] | MEK | RAF | Inhibitor | Enzymes

Orally available dual RAF kinase/EGFR inhibitor

Chemical name


Source information

Sold in collaboration with Chemietek

Parent CAS No.


The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...